Zhejiang Ausun Pharmaceutical (603229.SH): Receives Drug Registration Certificate for Imatinib Mesylate Tablets

Stock News2025-09-16

Zhejiang Ausun Pharmaceutical Co.,Ltd. (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd. ("Qizheng Pharmaceutical"), has received a Drug Registration Certificate for Imatinib Mesylate Tablets approved and issued by the National Medical Products Administration.

According to the announcement, Imatinib Mesylate Tablets is the world's first anti-tumor molecular targeted drug, used for treating patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, as well as patients with unresectable or metastatic malignant gastrointestinal stromal tumors (GIST).

The active ingredient imatinib is a tyrosine kinase inhibitor that can effectively inhibit the Philadelphia chromosome gene, preventing the catalysis of phosphorylation reactions and causing loss of chromosomal function, thereby inhibiting abnormal white blood cell proliferation. It can also bind to the active site of tyrosine kinase and block its activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187535653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187535653","market":"fut","top_or_hot":-1,"title":"Zhejiang Ausun Pharmaceutical (603229.SH): Receives Drug Registration Certificate for Imatinib Mesylate Tablets","media":"Stock News","content":"<p>Zhejiang Ausun Pharmaceutical Co.,Ltd. (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd. (\"Qizheng Pharmaceutical\"), has received a Drug Registration Certificate for Imatinib Mesylate Tablets approved and issued by the National Medical Products Administration.</p>\n<p>According to the announcement, Imatinib Mesylate Tablets is the world's first anti-tumor molecular targeted drug, used for treating patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, as well as patients with unresectable or metastatic malignant gastrointestinal stromal tumors (GIST).</p>\n<p>The active ingredient imatinib is a tyrosine kinase inhibitor that can effectively inhibit the Philadelphia chromosome gene, preventing the catalysis of phosphorylation reactions and causing loss of chromosomal function, thereby inhibiting abnormal white blood cell proliferation. It can also bind to the active site of tyrosine kinase and block its activity.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Ausun Pharmaceutical (603229.SH): Receives Drug Registration Certificate for Imatinib Mesylate Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Ausun Pharmaceutical (603229.SH): Receives Drug Registration Certificate for Imatinib Mesylate Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-16 16:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Ausun Pharmaceutical Co.,Ltd. (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd. (\"Qizheng Pharmaceutical\"), has received a Drug Registration Certificate for Imatinib Mesylate Tablets approved and issued by the National Medical Products Administration.</p>\n<p>According to the announcement, Imatinib Mesylate Tablets is the world's first anti-tumor molecular targeted drug, used for treating patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, as well as patients with unresectable or metastatic malignant gastrointestinal stromal tumors (GIST).</p>\n<p>The active ingredient imatinib is a tyrosine kinase inhibitor that can effectively inhibit the Philadelphia chromosome gene, preventing the catalysis of phosphorylation reactions and causing loss of chromosomal function, thereby inhibiting abnormal white blood cell proliferation. It can also bind to the active site of tyrosine kinase and block its activity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603229","symbol_name":"奥翔药业","start_time":0,"source_url":"","article_id":"1187535653","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187535653","pubTimestamp":1758010583,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Ausun Pharmaceutical Co.,Ltd. (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd. (\"Qizheng Pharmaceutical\"), has received a Drug Registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603229":"奥翔药业","BK0239":"医药制造"},"translate_title":"浙江奥逊药业（603229.SH）：甲磺酸伊马替尼片获药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603229":1},"content_text":"Zhejiang Ausun Pharmaceutical Co.,Ltd. (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd. (\"Qizheng Pharmaceutical\"), has received a Drug Registration Certificate for Imatinib Mesylate Tablets approved and issued by the National Medical Products Administration.\nAccording to the announcement, Imatinib Mesylate Tablets is the world's first anti-tumor molecular targeted drug, used for treating patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, as well as patients with unresectable or metastatic malignant gastrointestinal stromal tumors (GIST).\nThe active ingredient imatinib is a tyrosine kinase inhibitor that can effectively inhibit the Philadelphia chromosome gene, preventing the catalysis of phosphorylation reactions and causing loss of chromosomal function, thereby inhibiting abnormal white blood cell proliferation. It can also bind to the active site of tyrosine kinase and block its activity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187535653","isCrawlerRequest":true}